Cita APA

Shady, W., Petre, E. N., Vakiani, E., Ziv, E., Gonen, M., Brown, K. T., . . . Sofocleous, C. T. (2017). Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget.

Chicago Style Citation

Shady, Waleed, et al. "Kras Mutation Is a Marker of Worse Oncologic Outcomes After Percutaneous Radiofrequency Ablation of Colorectal Liver Metastases." Oncotarget 2017.

Cita MLA

Shady, Waleed, et al. "Kras Mutation Is a Marker of Worse Oncologic Outcomes After Percutaneous Radiofrequency Ablation of Colorectal Liver Metastases." Oncotarget 2017.